TOMI Secures New Contract with East Coast University
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 59 minutes ago
0mins
Should l Buy TOMZ?
Source: Newsfilter
- Contract Expansion: TOMI Environmental Solutions has secured a second installation contract for its SteraMist Hybrid System at a prestigious historic research university on the East Coast, further solidifying its partnership and showcasing its leadership in disinfection and decontamination solutions.
- Laboratory Safety Enhancement: This project will focus on the university's laboratory areas, aiming to enhance their rigorous safety and sterilization protocols, ensuring reliable decontamination solutions in high-risk environments, thereby improving overall operational safety for the institution.
- Successful Integration: TOMI will collaborate with familiar contractors to ensure seamless integration of the SteraMist Hybrid System, demonstrating the company's commitment to providing high-level automated decontamination solutions that meet the stringent requirements of esteemed educational and research institutions.
- Increased Market Trust: COO E.J. Shane stated that this partnership not only highlights TOMI's ongoing dedication to excellence in disinfection technologies but also reinforces its trusted position in the healthcare and research sectors, indicating potential for more market opportunities in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TOMZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TOMZ
Wall Street analysts forecast TOMZ stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.806
Low
3.50
Averages
3.50
High
3.50
Current: 0.806
Low
3.50
Averages
3.50
High
3.50

No data
About TOMZ
TOMI Environmental Solutions, Inc. is a bacteria decontamination and infectious disease control company. The Company is engaged in offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. The Company utilizes its Binary Ionization Technology (BIT) platform through its SteraMist brand of products. Its flagship product, SteraMist, uses its patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. SteraMist generates ionized Hydrogen Peroxide (iHP) using cold plasma science. Its products and services include SteraPak, SteraMist Surface Unit, SteraMist Environment System, SteraMist Total Disinfection Cart, SteraMist Transport, NV+, SteraMist Custom Engineered System, Hybrid, SteraMist Integrated System, Stainless Steel 90 Degree Applicator and iHP Corporate Service Decontamination.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Contract Expansion: TOMI Environmental Solutions has secured a second installation contract for its SteraMist Hybrid System at a prestigious historic research university on the East Coast, further solidifying its partnership and showcasing its leadership in disinfection and decontamination solutions.
- Laboratory Safety Enhancement: This project will focus on the university's laboratory areas, aiming to enhance their rigorous safety and sterilization protocols, ensuring reliable decontamination solutions in high-risk environments, thereby improving overall operational safety for the institution.
- Successful Integration: TOMI will collaborate with familiar contractors to ensure seamless integration of the SteraMist Hybrid System, demonstrating the company's commitment to providing high-level automated decontamination solutions that meet the stringent requirements of esteemed educational and research institutions.
- Increased Market Trust: COO E.J. Shane stated that this partnership not only highlights TOMI's ongoing dedication to excellence in disinfection technologies but also reinforces its trusted position in the healthcare and research sectors, indicating potential for more market opportunities in the future.
See More
- Surge in Demand: The ongoing virus outbreaks on cruise ships and public facilities have rapidly increased the demand for TOMI's SteraMist technology, which is expected to create long-term growth opportunities for the company, particularly in high-density travel environments.
- Significant Technological Advantage: SteraMist employs ionized hydrogen peroxide technology to rapidly disinfect air and surfaces while minimizing downtime, having been validated in high-risk sectors such as healthcare, pharmaceuticals, and transportation, highlighting its critical role in infection control.
- Accelerated Industry Transformation: As consumer awareness of sanitation standards intensifies, travel operators may be compelled to market advanced disinfection measures as a competitive differentiator, thereby enhancing customer trust and protecting occupancy rates.
- Clear Strategic Positioning: TOMI's unique positioning in infection prevention, hospitality safety, and biosecurity infrastructure makes it a potential leader in the large-scale disinfection market amid heightened global public health concerns.
See More
- Significant Revenue Growth: In Q1 2026, TOMI reported a 5% year-over-year revenue increase and a 67% sequential rise, with applicator sales surpassing total sales for all of 2025, indicating strong market demand and product acceptance.
- Order and Service Expansion: By the end of Q1 2026, TOMI's backlog grew from $1.6 million at the end of 2025 to $2.2 million, alongside receiving 440,000 annual purchase orders for recurring decontamination services, reflecting a robust customer base in the medical technology sector.
- International Market Authorizations: The company secured product authorizations in the UK, Netherlands, Germany, Belgium, Denmark, and Hungary during Q1 2026, accelerating its international expansion and enhancing its global market share.
- Strategic Merger Plans: TOMI intends to merge with Carbonium Core, Inc., with an enterprise valuation of $120 million under the LOI, aiming to finalize definitive agreements by May 30, 2026, showcasing its proactive strategy to expand operations and strengthen market competitiveness.
See More
- Technology Approval Expansion: TOMI's Binary Ionization Technology has received formal approval in Belgium, Denmark, Germany, and Hungary, marking an expansion of the company's authorizations in the EU and enhancing its competitive position in the medical, commercial, and industrial sectors.
- Accelerated Market Access: Under the EU's Biocidal Products Regulation, TOMI's products can achieve mutual recognition in multiple countries, expected to expedite market entry in Austria, France, Ireland, and others, reducing the time and costs associated with repeated authorizations.
- Strategic Growth Potential: COO E.J. Shane stated that this expansion not only reflects the company's commitment to effective disinfection solutions but also lays the groundwork for future sales growth in the European market, anticipated to deliver greater value to shareholders.
- Wide Product Application: TOMI's Binary Ionization Technology is widely utilized in various commercial structures, including hospitals, schools, and hotels, demonstrating its adaptability and growth potential across diverse markets.
See More








